| |
---|
| Detailed Price Information Link |
BACTERIA | How to read the following data (Example) |
Name: | Tissierella carlieri Alauzet et al. 2014 |
DSM No.: | 23816, Type strain dsm-23816 dsm23816 dsm 23816 Tissierella carlieri |
Strain designation: | AIP 268.01, LBN 295 |
Other collection no. or WDCM no.: | CCUG 60010 |
Isolated from: | human stump wound (clinical specimen) |
Country: | France Nancy |
Date of sampling: | 29.06.2001 |
Nagoya Protocol Restrictions: | France requires a benefit-sharing declaration for French genetic resources at the time of utilization, i.e., conducting research. France considers access to genetic resources when utilization begins and not when the initial collection of the material took place and applies to material both in-situ and ex-situ and users within and outside of France.
To comply with French law, you, the user need to make a Declaration regarding access to genetic resources and benefit-sharing arising from your non-commercial utilisation of genetic resources. The steps are the following:
1. File a declaration via the CERFA form n. 15786 (https://www.formulaires.service-public.fr/gf/getAnnexe.do?cerfaAnnexe=1&cerfaFormulaire=15786*02) or by electronic procedure (https://www.demarches-simplifiees.fr/commencer/apa-declaration-pmorale)
2. Await approval by the Ministry for the Ecological Transition, the competent national authority
3. Respond to any requests for more information from the competent national authority
4. Receive an acknowledgment of receipt by the competent national authority certifying the prior informed consent (PIC) and establishment of mutually agreed terms (MAT) regarding benefit-sharing. This procedure shall not exceed 2 months.
For more information about this topic please see the Access and Benefit-Sharing Clearing House: https://absch.cbd.int/en/countries/FR
For more information about the commercial use of this genetic resources please contact: justiziariat@dsmz.de |
History: | <- C. Alauzet, Hôpital Brabois Adultes, Centre Hospitalier Universitaire de Nancy; LBN 295 <- F. Mory |
Genbank accession numbers: | 16S rRNA gene: GQ461821 |
Cultivation conditions: | Medium 104 , anaerobic, 37°C
Please follow special instructions: 'Cultivation of Anaerobes'
Complete DSMZ Media List |
Summary and additional information: | <- C. Alauzet, Hôpital Brabois Adultes, Centre Hospitalier Universitaire de Nancy; LBN 295 <- F. Mory. Human stump wound (clinical specimen); France, Nancy. Type strain. Taxonomy/description (18897, 19998). Sequence accession no. 16S rRNA gene: GQ461821. (Medium 104, 37°C, anaerobic). |
Literature: | 18897, 19998 |
Risk group: | 2 (provisional classification by DSMZ) |
Restrictions: | Act dealing with the prevention & control of infectious diseases in man (Infektionsschutzgesetz), Category A1
|
Supplied as: | Delivery form | | Prices | | Freeze Dried | | 100,- € | Active culture on request | | 240,- € | DNA | | 150,- € | | Price Category for this culture: 1 |
Freight and handling charges will be added. See price list. Note: Freight charges for Risk Group 2 microorganisms will apply. |
Other cultures: | All DSMZ cultures of the species |
| Print data sheet |